Significant developments on Tuesday regarding the Johnson & Johnson monosodium vaccine against Covid-19. For its part, the White House assures that the suspension of its vaccine, due to the occurrence of severe cases of thromboembolism, “Will not have a significant impact” on the US immunization campaign.
“This announcement will not have a serious impact on the vaccination campaign,” said Jeff Zayenz, the US government’s pandemic coordinator. As the official explained, to date this preparation represents less than 5% of vaccines administered in the US.
According to Zayenz, the decision to suspend its use was taken “for precautionary reasons”. The United States has secured several doses of Pfizer and Moderna vaccines to cover 300 million Americans, he added.
Earlier today, the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) announced that they were suspending its use. J&J vaccine after Six vaccinated (among the approximately 6.8 million who received it) developed a rare blood clotting disorder, as broadcast by Reuters and Agence France-Presse and rebroadcast by the Athenian News Agency. Suspension does not affect the other two approved vaccines, Pfizer and Moderna.
The FDA, in a press conference held this morning, confirmed to the press that a woman died of a thromboembolism while a second was being treated in critical condition after being given the J&J vaccine. In all, said Peter Marx, chief of staff, six people, aged 18 to 48 years, showed symptoms of cerebral thrombosis, combined with a low platelet count, 6 to 13 days after vaccination.
The CDC has scheduled a meeting of immunization experts for tomorrow, Wednesday. Zayenz and Dr. Anthony Fauci, the top US epidemiologist, will attend the White House briefing later today.